XSWX
MED
Market cap1.23bUSD
Oct 09, Last price
82.40CHF
1D
0.98%
1Q
-9.65%
IPO
31.84%
Name
Medartis Holding AG
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Medartis Holding AG is a global medical technology firm that develops, manufactures, and distributes implantable solutions. These advanced medical devices are utilized worldwide for the surgical stabilization of bone fractures in both the upper and lower extremities, in addition to addressing complex cranio-maxillofacial surgical needs. The company's portfolio features osteosynthesis instruments, marketed under the APTUS and MODUS brands, specifically designed for various body regions including the hand, wrist, elbow, shoulder, foot, and ankle, as well as for facial and skull procedures involving the mandible, midface, orthognathic structures, and cranium. Medartis serves a diverse clientele comprising surgeons, hospitals, medical centers, and group purchasing organizations. The company, founded in 1997, is headquartered in Basel, Switzerland.
Related entities
Subsidiaries (2)
Medartis AG
MEDARTIS INTERNATIONAL FINANCE SAS
Key people
Non-Executive Vice Chairman of the Board · since 2021
Caroline Knoeri
Chief Human Resources Officer, Member of the Executive Management Board · since 2025
Marc Ammann
Executive Vice President - R&D and Innovation, Member of the Executive Management Board · since 2025
Mario Della Casa
Chief Operating Officer, Member of the Executive Management Board · since 2022
Dirk Kirsten
Chief Financial Officer, Member of the Executive Management Board · since 2021
Manuel Schaer
Chief Technology Officer, Member of the Executive Management Board · since 2020
Chief Executive Officer, Member of the Executive Management Board · since 2024
Mareike Loch
President - EMEA, Member of the Executive Management Board · since 2024
Inge Maes
Chief Human Resource Officer, Member of the Executive Management Board · since 2024
David Thoni
US President, Member of the Executive Management Board · since 2025
Non-Executive Independent Chairman of the Board · since 2022
Jennifer Dean
Non-Executive Independent Member of the Board · since 2024
Willi Miesch
Non-Executive Independent Member of the Board · since 2023
Ciro Roemer
Non-Executive Independent Member of the Board · since 2022
Nadia Schmidt
Non-Executive Independent Member of the Board · since 2022
Martha Shadan
Non-Executive Independent Member of the Board · since 2024
Non-Executive Independent Member of the Board · since 2022
Headquarters & legal address
Hochbergerstr. 60E
Basel, BS 4057
CH
Basel, BS 4057
CH
Valuation
Title CHF in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||